ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,042Medicare Part D Prescriptions Filled, Including Refills

Rank: 33 out of 546

$703K Total Retail Price of All Prescriptions

Rank: 24 out of 546

362 Patients Receiving at Least One Drug in Part D
71%Patients 65 Years and Older
73% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maine
Lower avg

Schedule Two
Controlled Substances

20% of this provider’s 362 patients filled at least one prescription for a schedule two drug, compared to an average of 9%.

Schedule Three
Controlled Substances

12% of this provider’s 362 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

1% of this provider’s 6,601 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

26% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$78 was the average price of a prescription from this provider, compared to $65 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maine
LISINOPRIL 347 283 1 1
OMEPRAZOLE 281 211 2 4
LEVOTHYROXINE SODIUM 279 216 3 3
WARFARIN SODIUM 230 204 4 13
SIMVASTATIN 211 155 5 2
SERTRALINE HCL 172 134 6 14
PREDNISONE 167 147 7 29
AMLODIPINE BESYLATE 166 146 8 9
HYDROCODONE-ACETAMINOPHEN 162 71 S3 9 8
METFORMIN HCL 159 114 10 10
METOPROLOL SUCCINATE 151 123 11 17
FUROSEMIDE 146 133 12 5
METOPROLOL TARTRATE 142 132 13 6
GABAPENTIN 140 107 14 16
CRESTOR 137 113 15 36
OXYCODONE HCL 133 38 S2 16 15
ADVAIR DISKUS 129 93 17 20
TRAZODONE HCL 124 80 18 25
ATORVASTATIN CALCIUM 123 102 19 11
HYDROCHLOROTHIAZIDE 121 104 20 7
PANTOPRAZOLE SODIUM 116 94 21 18
LISINOPRIL-HYDROCHLOROTHIAZIDE 114 100 22 49
FLUOXETINE HCL 112 66 23 39
FENTANYL 110 51 S2 24 50
ZOLPIDEM TARTRATE 97 53 25 26
MELOXICAM 96 80 26 58
CYMBALTA 94 27 27 37
SPIRIVA 77 69 28 28
OXYCONTIN 77 31 S2 28 75
ESCITALOPRAM OXALATE 72 47 30 66
DEXILANT 71 19 31 109
PROAIR HFA 70 40 32 27
AMITRIPTYLINE HCL 69 19 R 33 48
TRAMADOL HCL 68 54 34 19
LOSARTAN POTASSIUM 66 60 35 24
FENOFIBRATE 65 64 36 87
ISOSORBIDE MONONITRATE ER 63 63 37 32
RANITIDINE HCL 63 47 37 23
ALLOPURINOL 62 62 39 41
INSULIN SYRINGE 60 58 40 85
TAMSULOSIN HCL 54 39 41 35
PAROXETINE HCL 52 44 42 43
ROPINIROLE HCL 50 29 43 64
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.